The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy.
Ali A, Mekhaeil B, Biziotis OD, Tsakiridis EE, Ahmadi E, Wu J, Wang S, Singh K, Menjolian G, Farrell T, Mesci A, Liu S, Berg T, Bramson JL, Steinberg GR, Tsakiridis T.
Ali A, et al.
Commun Biol. 2023 Sep 8;6(1):919. doi: 10.1038/s42003-023-05289-w.
Commun Biol. 2023.
PMID: 37684337
Free PMC article.